Serum and Urine Biomarkers for Human Renal Cell Carcinoma

Abstract EN

Renal cell carcinoma (RCC) diagnosis is mostly achieved incidentally by imaging provided for unrelated clinical reasons.

The surgical management of localized tumors has reported excellent results.

The therapy of advanced RCC has evolved considerably over recent years with the widespread use of the so-called “targeted therapies.” The identification of molecular markers in body fluids (e.g., sera and urine), which can be used for screening, diagnosis, follow-up, and monitoring of drug-based therapy in RCC patients, is one of the most ambitious challenges in oncologic research.

Although there are some promising reports about potential biomarkers in sera, there is limited available data regarding urine markers for RCC.

The following review reports some of the most promising biomarkers identified in the biological fluids of RCC patients.